Hereditary Angioedema

Global Market Trajectory & Analytics

MCP16460

EXECUTIVE ENGAGEMENTS

POOL

372
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

74
Interactions with Platform & by Email

PARTICIPANTS

13
Unique # Participated

VALIDATIONS

6
Responses Validated*

COMPANIES

46
Responses Validated*
* Login for a full stack data experience

DATE

APR 2021

TABLES

156

PAGES

232

EDITION

9

PRICE

USD 4950

CODE

MCP16460


COMPETITIVE METRICS

COMPANY

D S N T

% *

ActiveSite Pharmaceuticals

BioCryst Pharmaceuticals, Inc.

CSL Ltd.

Dyax

HAEA

Ionis Pharmaceuticals, Inc.

Pharming Group NV

Pharvaris

Rezolute

Shire PLC

View More...

SUBMIT
Note: Best viewed in Landscape Mode
  

HIGHLIGHTS & REPORT INDEX

Amid the COVID-19 crisis, the global market for Hereditary Angioedema estimated at US$2.3 Billion in the year 2020, is projected to reach a revised size of US$3.9 Billion by 2027, growing at a CAGR of 7.8% over the analysis period 2020-2027. C1 Esterase Inhibitor, one of the segments analyzed in the report, is projected to record a 8.7% CAGR and reach US$2.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Selective Bradykinin B2 Receptor Antagonist segment is readjusted to a revised 6.5% CAGR for the next 7-year period.
The Hereditary Angioedema market in the U.S. is estimated at US$690.1 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$683.6 Million by the year 2027 trailing a CAGR of 7.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.3% and 6.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 6.2% CAGR.
In the global Kallikrein Inhibitor segment, USA, Canada, Japan, China and Europe will drive the 7.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$89.6 Million in the year 2020 will reach a projected size of US$149.1 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$451.7 Million by the year 2027.

SELECT PLAYERS

BioCryst Pharmaceuticals, Inc.; CSL Ltd.; iBio, Inc.; Ionis Pharmaceuticals, Inc.; Pharming Group NV; Shire PLC

SEGMENTS

» Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels) » Drug Class (C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes) » Route of Administration (Intravenous, Subcutaneous Injection, Oral)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for Hereditary Angioedema by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Hereditary Angioedema by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Hereditary Angioedema by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
World Current & Future Analysis for C1 Esterase Inhibitor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for C1 Esterase Inhibitor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for C1 Esterase Inhibitor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Selective Bradykinin B2 Receptor Antagonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Selective Bradykinin B2 Receptor Antagonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Selective Bradykinin B2 Receptor Antagonist by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Kallikrein Inhibitor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Kallikrein Inhibitor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Kallikrein Inhibitor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Intravenous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Subcutaneous injection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Subcutaneous injection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Subcutaneous injection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Hospital pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Hospital pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Hospital pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Retail pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Retail pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Retail pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
UNITED STATES
USA Current & Future Analysis for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA Historic Review for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Hereditary Angioedema by Drug Class - Percentage Breakdown of Value Sales for C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes for the Years 2012, 2020 & 2027
USA Current & Future Analysis for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA Historic Review for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Hereditary Angioedema by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous injection and Oral for the Years 2012, 2020 & 2027
USA Current & Future Analysis for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA Historic Review for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Hereditary Angioedema by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Other Distribution Channels for the Years 2012, 2020 & 2027
CANADA
Canada Current & Future Analysis for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Hereditary Angioedema by Drug Class - Percentage Breakdown of Value Sales for C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes for the Years 2012, 2020 & 2027
Canada Current & Future Analysis for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Hereditary Angioedema by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous injection and Oral for the Years 2012, 2020 & 2027
Canada Current & Future Analysis for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Hereditary Angioedema by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Other Distribution Channels for the Years 2012, 2020 & 2027
JAPAN
Japan Current & Future Analysis for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Hereditary Angioedema by Drug Class - Percentage Breakdown of Value Sales for C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes for the Years 2012, 2020 & 2027
Japan Current & Future Analysis for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Hereditary Angioedema by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous injection and Oral for the Years 2012, 2020 & 2027
Japan Current & Future Analysis for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Hereditary Angioedema by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Other Distribution Channels for the Years 2012, 2020 & 2027
CHINA
China Current & Future Analysis for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China Historic Review for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Hereditary Angioedema by Drug Class - Percentage Breakdown of Value Sales for C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes for the Years 2012, 2020 & 2027
China Current & Future Analysis for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China Historic Review for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Hereditary Angioedema by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous injection and Oral for the Years 2012, 2020 & 2027
China Current & Future Analysis for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China Historic Review for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Hereditary Angioedema by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Other Distribution Channels for the Years 2012, 2020 & 2027
EUROPE
Europe Current & Future Analysis for Hereditary Angioedema by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Europe Historic Review for Hereditary Angioedema by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Hereditary Angioedema by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
Europe Current & Future Analysis for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Hereditary Angioedema by Drug Class - Percentage Breakdown of Value Sales for C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes for the Years 2012, 2020 & 2027
Europe Current & Future Analysis for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Hereditary Angioedema by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous injection and Oral for the Years 2012, 2020 & 2027
Europe Current & Future Analysis for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Hereditary Angioedema by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Other Distribution Channels for the Years 2012, 2020 & 2027
FRANCE
France Current & Future Analysis for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France Historic Review for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Hereditary Angioedema by Drug Class - Percentage Breakdown of Value Sales for C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes for the Years 2012, 2020 & 2027
France Current & Future Analysis for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France Historic Review for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Hereditary Angioedema by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous injection and Oral for the Years 2012, 2020 & 2027
France Current & Future Analysis for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France Historic Review for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Hereditary Angioedema by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Other Distribution Channels for the Years 2012, 2020 & 2027
GERMANY
Germany Current & Future Analysis for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Hereditary Angioedema by Drug Class - Percentage Breakdown of Value Sales for C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes for the Years 2012, 2020 & 2027
Germany Current & Future Analysis for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Hereditary Angioedema by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous injection and Oral for the Years 2012, 2020 & 2027
Germany Current & Future Analysis for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Hereditary Angioedema by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Other Distribution Channels for the Years 2012, 2020 & 2027
ITALY
Italy Current & Future Analysis for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Hereditary Angioedema by Drug Class - Percentage Breakdown of Value Sales for C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes for the Years 2012, 2020 & 2027
Italy Current & Future Analysis for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Hereditary Angioedema by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous injection and Oral for the Years 2012, 2020 & 2027
Italy Current & Future Analysis for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Hereditary Angioedema by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Other Distribution Channels for the Years 2012, 2020 & 2027
UNITED KINGDOM
UK Current & Future Analysis for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK Historic Review for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Hereditary Angioedema by Drug Class - Percentage Breakdown of Value Sales for C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes for the Years 2012, 2020 & 2027
UK Current & Future Analysis for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK Historic Review for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Hereditary Angioedema by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous injection and Oral for the Years 2012, 2020 & 2027
UK Current & Future Analysis for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK Historic Review for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Hereditary Angioedema by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Other Distribution Channels for the Years 2012, 2020 & 2027
REST OF EUROPE
Rest of Europe Current & Future Analysis for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Hereditary Angioedema by Drug Class - Percentage Breakdown of Value Sales for C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes for the Years 2012, 2020 & 2027
Rest of Europe Current & Future Analysis for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Hereditary Angioedema by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous injection and Oral for the Years 2012, 2020 & 2027
Rest of Europe Current & Future Analysis for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Hereditary Angioedema by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Other Distribution Channels for the Years 2012, 2020 & 2027
ASIA-PACIFIC
Asia-Pacific Current & Future Analysis for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Hereditary Angioedema by Drug Class - Percentage Breakdown of Value Sales for C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes for the Years 2012, 2020 & 2027
Asia-Pacific Current & Future Analysis for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Hereditary Angioedema by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous injection and Oral for the Years 2012, 2020 & 2027
Asia-Pacific Current & Future Analysis for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Hereditary Angioedema by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Other Distribution Channels for the Years 2012, 2020 & 2027
REST OF WORLD
Rest of World Current & Future Analysis for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Hereditary Angioedema by Drug Class - C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Hereditary Angioedema by Drug Class - Percentage Breakdown of Value Sales for C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor and Other Drug Classes for the Years 2012, 2020 & 2027
Rest of World Current & Future Analysis for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Hereditary Angioedema by Route Of Administration - Intravenous, Subcutaneous injection and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Hereditary Angioedema by Route Of Administration - Percentage Breakdown of Value Sales for Intravenous, Subcutaneous injection and Oral for the Years 2012, 2020 & 2027
Rest of World Current & Future Analysis for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Hereditary Angioedema by Distribution Channel - Hospital pharmacies, Retail pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Hereditary Angioedema by Distribution Channel - Percentage Breakdown of Value Sales for Hospital pharmacies, Retail pharmacies and Other Distribution Channels for the Years 2012, 2020 & 2027
Total Companies Profiled: 46

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com